...SVP of chemistry and biology business unit at Shanghai Medicilon Inc. (Shanghai:688202).Neuroscience and immuno-oncology company BioXcel...
...VP of R&D. BC Staff Intercept Blood System for plasma (amotosalen, Intercept Plasma System (S-59)) TScan Therapeutics Insilico Biotechnology Kira Biotech BioXcel Re-Vana...

...Randy Scott to the board. Scott was executive chairman and CEO of Invitae Corp. (NYSE:NVTA). BioXcel...

...OTCQX:RHHBY), where she was global head of the pharma’s neuromuscular franchise. Neuroscience and immuno-oncology play BioXcel...
...VP of clinical development at Merus N.V. (NASDAQ:MRUS). Robin Sawka, BioCentury Staff Nurix Therapeutics Inc. Xilio Therapeutics Inc. Edgewise Therapeutics BioXcel...

...Inc. Dewpoint Therapeutics FerGene Inc. Adverum Biotechnologies Inc. Epsilen Bio s.r.l. Kaleido Biosciences Inc. Laboratory for Advanced Medicine Inc. Mundipharma International Ltd. MacroGenics Inc. BioXcel...

...Fund I raised. Fund I has made 13 investments, including in neuroscience and immuno-oncology company BioXcel...
...dermatology, cancer and cardiovascular biotechs and innovative technology companies. Gore Range Capital, New York, N.Y. Jennie Walters BioXcel...

...cells in peripheral blood and weight loss. Next steps include identifying additional dual DPP-8/DPP-9 inhibitors. BioXcel...

...NASDAQ:FIXX) 3/27/18 $165.6 $598.9 $814.8 36% Arcus Biosciences Inc. (NYSE:RCUS) 3/14/18 $138.0 $656.3 $543.2 -17% BioXcel...

...Artificial intelligence company BioXcel Therapeutics Inc. (NASDAQ:BTAI) raised $60 million on March 8 through the sale...
...by Barclays, UBS, BMO and Canaccord Genuity. The price valued the company at $172.1 million. BioXcel...
...both programs into Phase II proof-of-concept studies this year. BioXcel Therapeutics Inc. (NASDAQ:BTAI), Branford, Conn. Sandi Wong BioXcel...

...by Barclays, UBS, BMO and Canaccord Genuity. The price valued the company at $172.1 million. BioXcel...
...AI to identify new indications for approved or clinically validated products. An IV formulation of BioXcel's...
...cancer. The biotech plans to move both programs into Phase II proof-of-concept studies this year. Sandi Wong BXCL501 BXCL701 BioXcel...

...Artificial intelligence company BioXcel Therapeutics Inc. (Branford, Conn.) proposed on Feb. 13 to raise up to...
...Genuity. BioXcel Therapeutics is a subsidiary of BioXcel Corp. (Branford, Conn.). BioXcel Therapeutics Inc., Branford, Conn. Sandi Wong BioXcel Corp. BioXcel...